These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 12767104)

  • 1. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
    Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
    Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
    Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
    Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma.
    Bozzi F; Collini P; Aiello A; Barzanò E; Gambirasio F; Podda M; Meazza C; Ferrari A; Luksch R
    Anticancer Res; 2008; 28(3A):1565-9. PubMed ID: 18630512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
    Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
    Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
    Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
    Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow.
    Okcu MF; Wang RY; Bueso-Ramos C; Schober W; Weidner D; Andrassy R; Blakely M; Russell H; Ozkan A; Kuttesch J; Andreeff M; Chan KW; Ater J
    Pediatr Blood Cancer; 2005 Nov; 45(6):787-95. PubMed ID: 15929127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients.
    Corrias MV; Haupt R; Carlini B; Parodi S; Rivabella L; Garaventa A; Pistoia V; Dallorso S
    Clin Cancer Res; 2006 Oct; 12(19):5680-5. PubMed ID: 17020970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.
    Ross AA; Miller GW; Moss TJ; Kahn DG; Warner NE; Sweet DL; Louie KG; Schneidermann E; Pecora AL; Meagher RC
    Bone Marrow Transplant; 1995 Jun; 15(6):929-33. PubMed ID: 7581093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirates for neuroblastoma.
    Lee ST; Suh YL; Ko YH; Ki CS; Sung KW; Kim HJ; Kim JW; Kim SH; Chueh H; Lee SH; Yoo KH; Koo HH
    Pediatr Blood Cancer; 2010 Aug; 55(2):273-8. PubMed ID: 20582938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
    Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
    Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
    Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
    Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.